| 1 |
S. A Roberts, "High-throughput screening approaches for investigating drug metabolism and pharmacokinetics", Xenobiotica., Vol. 31, pp. 557-589, 2001.
DOI
ScienceOn
|
| 2 |
M. Dias, R. Mittal, R. McKinnon and M. Sorich, "Systematic statistical comparison of comparative molecular similarity indices analysis molecular fields for computer-aided lead optimization", J. Chem Inf. Model., Vol. 46, pp. 2015-2021, 2006.
DOI
ScienceOn
|
| 3 |
R. D. Cramer, D. E. Patterson and J. D. Bunce, "Comparative molecular field analysis (CoMFA) I. Effect of shape on binding of steroids to carrier proteins", J. Am. Chem. Soc., Vol. 110, pp. 5959-5967, 1988.
DOI
ScienceOn
|
| 4 |
G. Klebe, U. Abraham and T. Mietzner, "Molecular Similarity Indices in a Comparative Analysis (CoMSIA) of Drug Molecules to Correlate and Predict Their Biological Activity", J. Med. Chem., Vol. 37, pp. 4130-4146, 1994.
DOI
ScienceOn
|
| 5 |
L. L. Zhu, T. J. Hou, L. R. Chen and X. J. Xu, "3D QSAR Analyses of Novel Tyrosine Kinase Inhibitors Based on Pharmacophore Alignment", J. Chem. Inf. Comput. Sci., Vol. 41, pp. 1032-1040, 2001.
DOI
ScienceOn
|
| 6 |
G. Klebe, "Comparative Molecular Similarity Indices Analysis: CoMSIA", Perspect. Drug Discovery Des., Vol. 12, pp. 87-104, 1998.
|
| 7 |
K. H. Kim, "Comparative Molecular Similarity Field Analysis (CoMFA), In dean, P. M. (Ed.) Molecular similarity in drug design", Blackie Academic & Professional, London., pp. 291-331, 1995.
|
| 8 |
L. Belvisi, G. Bravi, G. Catalano, M. Mabilia, A. Salimbeni and C. Scolastico, "A 3D QSAR CoMFA study of non-peptide angiotensin II receptor antagonists", J. Comput.-Aided Mol. Des., Vol. 10, pp. 567-582, 1996.
DOI
ScienceOn
|
| 9 |
K. H. Kim, G. Greco and E. Novellino, "A critical review of recent CoMFA applications", Perspect. Drug Discovery Des., Vol. 12, pp. 257-315, 1998.
|
| 10 |
R. T. Kroemer, P. Hecht and K. R. Liedl, "Different electrostatic descriptors in comparative molecular field analysis: A comparison of molecular electrostatic and Coulomb potentials", J. Comput. Chem., Vol. 17, pp. 1296-1308, 1996.
DOI
ScienceOn
|
| 11 |
A. Shagufta, G. Kumar, M. Panda, I. Siddiqi, "CoMFA and CoMSIA 3D-QSAR analysis of diaryloxy-methano-phenanthrene derivatives as antitubercular agents", J. Mol. Model., Vol. 13, pp. 99-109, 2007.
|
| 12 |
Y. L. Li, A. D. Mackerell, M. J. Egorin, M. F. Ballesteros, D. M. Rosen, Y. Y. Wu, D. A. Blamble and P. S. Callery, "Comparative molecular field analysis-based predictive model of structure function relationships of polyamine transport inhibitors in L1210", Cancer. Res., Vol. 57, pp. 234-239, 1997.
|
| 13 |
H. Gohlke, S. Schwarz, D. Gundisch, M. C. Tilotta, A. Weber, T. Wegge, and G. Seitz, "3D QSAR Analyses-Guided Rational Design of Novel Ligands for the ( 4)2( 2)3 Nicotinic Acetylcholine Receptor", J. Med. Chem., Vol. 46, pp. 2031-2048, 2003.
DOI
ScienceOn
|
| 14 |
W. Tong, E. R. Collantes, Y. Chen and W. J. Welsh, "A comparative molecular field analysis study of N-benzylpiperidines as acetylcholinesterase inhibitors", J. Med. Chem., Vol. 39, pp. 380-387, 1996.
DOI
ScienceOn
|
| 15 |
T. I. Opera, C. L. Waller and G. R. Marshall, "3D-QSAR of human immunodeficiency virus (I) protease inhibitors: 3. Interpretation of CoMFA results", Drug Des. Discovery., Vol. 12, pp. 29-51, 1994.
|
| 16 |
C. L. Waller, T. I. Opera, A. Giolitti and G. R. Marshall, "Three-dimensional QSAR of human immunodeficiency virus-I protease inhibitors: 1. A CoMFA study employing experimentally determined alignment rules", J. Med. Chem., Vol. 36, pp. 4152-4160, 1993.
DOI
ScienceOn
|
| 17 |
R. R. Mittal. R. A. McKinnon and M. J. Sorich, "Effect of steric molecular field settings on CoMFA predictivity", J. Mol. Model., Vol. 14, pp. 59-67, 2008.
DOI
ScienceOn
|
| 18 |
R. R. Mittal, L. Harris, R. A. McKinnon and M. J. Sorich, "Partial Charge Calculation Method Affects CoMFA QSAR Prediction Accuracy", J. Chem. Inf. Model., Vol. 49, pp. 704-709, 2009.
DOI
ScienceOn
|
webmaster
